Lu Xuan, Li Ying, Yang Yan, Zhuang Wanchuan, Chai Xingxing, Gong Chen
School of Life Sciences, Hefei Nomal University, Hefei, Anhui 230031, China.
Fudan University Affiliated Pudong Medical Center, Shanghai 201301, China.
J Oncol. 2023 Feb 22;2023:6017852. doi: 10.1155/2023/6017852. eCollection 2023.
Acute myeloid leukemia (AML) is a malignant clonal disease of the myeloid hematopoietic system. Clinically, standard treatment options include conventional chemotherapy as well as hematopoietic stem cell transplantation. Among them, chemotherapy has a remission rate of 60% to 80% and nearly 50% relapse in consolidation therapy. Some patients have a poor prognosis due to the presence of unfavorable factors such as advanced age, hematologic history, poor prognosis karyotype, severe infection, and organ insufficiency, which cannot tolerate or are not suitable for standard chemotherapy regimens, and scholars have tried to find new treatment strategies to improve this situation. In the pathogenesis and treatment of leukemia, epigenetics has received attention from experts and scholars.
To investigate the relationship between OLFML2A overexpression and AML patients.
From The Cancer Genome Atlas, researchers used the data of OLFML2A gene to analyze and study the pan-cancer using R language and then divided the high and low levels of this protein into two groups to study its relationship with the clinical characteristics of the disease. The relationship between the high levels of OLFML2A and various clinical features of the disease was studied with emphasis on the relationship between the high levels of OLFML2A and various clinical features of the disease. A multidimensional Cox regression analysis was also performed to study the factors affecting patient survival. The correlation between OLFML2A expression and immune infiltration through the immune microenvironment was analyzed. The researchers then conducted a series of studies to analyze the data collected in the study. The focus was on the relationship between the high levels of OLFML2A and immune infiltration. Gene ontology analysis was also performed to study the interactions between the different genes associated with this protein.
According to the pan-cancer analysis, OLFML2A was differentially expressed in different tumors. More importantly, the analysis of OLFML2A in the TCGA-AML database revealed that OLFML2A was highly expressed in AML. The researchers found that the high levels of OLFML2A were associated with different clinical features of the disease, and that the expression of the protein was different in different groups. Those patients with the high levels of OLFML2A were found to have substantially longer survival times compared to those with low-protein levels.
The OLFML2A gene is able to act as a molecular indicator involved in the diagnosis, prognosis, and immune process of AML. It improves the molecular biology prognostic system of AML, provides help for the selection of AML treatment options, and provides new ideas for future biologically targeted therapy of AML.
急性髓系白血病（AML）是髓系造血系统的恶性克隆性疾病。临床上，标准治疗方案包括传统化疗以及造血干细胞移植。其中，化疗的缓解率为60%至80%，巩固治疗中近50%会复发。一些患者由于存在高龄、血液病史、预后不良核型、严重感染和器官功能不全等不利因素，无法耐受或不适合标准化疗方案，预后较差，学者们一直在尝试寻找新的治疗策略来改善这种情况。在白血病的发病机制和治疗中，表观遗传学受到了专家学者的关注。
探讨OLFML2A过表达与AML患者之间的关系。
研究人员从癌症基因组图谱中提取OLFML2A基因的数据，使用R语言对泛癌进行分析研究，然后将该蛋白的高低水平分为两组，研究其与疾病临床特征的关系。重点研究OLFML2A高水平与疾病各种临床特征之间的关系，还进行了多维度Cox回归分析以研究影响患者生存的因素。通过免疫微环境分析OLFML2A表达与免疫浸润之间的相关性。研究人员随后进行了一系列研究以分析研究中收集的数据，重点是OLFML2A高水平与免疫浸润之间的关系，还进行了基因本体分析以研究与该蛋白相关的不同基因之间的相互作用。
根据泛癌分析，OLFML2A在不同肿瘤中存在差异表达。更重要的是，对TCGA-AML数据库中OLFML2A的分析显示，OLFML2A在AML中高表达。研究人员发现，OLFML2A高水平与疾病的不同临床特征相关，且该蛋白在不同组中的表达情况不同。与低蛋白水平的患者相比，OLFML2A高水平的患者生存时间明显更长。
OLFML2A基因能够作为参与AML诊断、预后和免疫过程的分子指标。它完善了AML的分子生物学预后系统，为AML治疗方案的选择提供帮助，并为未来AML的生物靶向治疗提供新思路。
